BDX · Becton, Dickinson and Company
$156.36
+4.67% last session
End-of-day data · updated 2026-07-28
Market cap
—
Enterprise value
$60B
Trailing P/E
27.8
Forward P/E
11.9
Dividend yield
3.0%
Beta
0.27
Avg volume
3M
Employees
60K
2D change
1.64%
5D change
3.89%
10D change
0.47%
30D change
1.92%
60D change
8.78%
MTD change
3.94%
YTD change
5.57%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BDX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
UBS
Buy$190
+21.5% vs priceBarclays
Overweight$204
+30.5% vs priceWells Fargo
Equal-Weight$161
+3.0% vs priceCitigroup
Buy$198
+26.6% vs priceJP Morgan
Neutral$175
+11.9% vs priceJefferies
Buy$190
+21.5% vs priceRBC Capital
Sector Perform$172
+10.0% vs priceBank of America
Neutral$207
+32.4% vs priceMorgan Stanley
Overweight$210
+34.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | UBS | Initiates | Buy | $0.00 → $190 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $190 → $180 |
| 2026-05-11 | Barclays | Maintains | Overweight | $202 → $204 |
| 2026-05-08 | Wells Fargo | Maintains | Equal-Weight | $157 → $161 |
| 2026-05-04 | TD Cowen | Maintains | Hold | $189 → $163 |
| 2026-04-17 | Piper Sandler | Maintains | Neutral | $170 → $159 |
| 2026-03-23 | Argus Research | Maintains | Buy | $230 → $180 |
| 2026-02-11 | Citigroup | Maintains | Buy | $232 → $198 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 67 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.1% above the 50-day MA ($149.73).
- Price vs 200-day MA: Trading 8.6% above the 200-day MA ($153.16).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.65) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($132.30) and high ($182.92).
BDX Price Chart
Loading chart for BDX…
Fundamentals
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.